NCT02172768View on ClinicalTrials.gov

Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

July 31, 2016

Conditions
Acute Graft Versus Host Disease Grade II-IVAllogeneic Stem Cell TransplantAcute Myeloid LeucaemiaMyelo Dysplastic Syndrome
Interventions
OTHER

alternate dosing

treatment for 8 days with intravenous micafungin twice weekly

OTHER

daily dosing

micafungin daily for 8 days

DRUG

micafungin

Trial Locations (2)

Unknown

UZ Leuven, Leuven

Radboudumc, Nijmegen

All Listed Sponsors
lead

Radboud University Medical Center

OTHER

NCT02172768 - Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease | Biotech Hunter | Biotech Hunter